Schmieder GJ, et al. - The efficacy, safety and tolerability of PF-04965842, an oral Janus Kinase 1 inhibitor were comprehensively assessed, in patients with moderate to severe plaque psoriasis. An improvement was noted in the patients when treatment with PF-04965842. This therapy was well tolerated in the study cohort.